Trial
NCT03624517
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Medical University of South Carolina
Collaborators
Ohio State University; University of Texas Southwestern Medical Center; University of Florida Health
Condition
Esophageal Varices
Intervention
Octreotide
Why stopped
Recruitment was severely affected due to COVID, so study was stopped prematurely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-20